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The nonsteroidal anti-inflammatory drug (NSAID) niflumic acid, a fenamate in structure, has many 
molecular targets, one of them being specific subtypes of the main inhibitory ligand-gated anion 
channel, the GABAA receptor. Here, we report on the effects of other fenamates and other classes 
of NSAIDs on brain picrotoxinin-sensitive GABAA receptors, using an autoradiographic assay with 
[
35
S]TBPS as a ligand on mouse brain sections. We found that the other fenamates studied 
(flufenamic acid, meclofenamic acid, mefenamic acid and tolfenamic acid) affected the 
autoradiographic signal at low micromolar concentrations in a facilitatory-like allosteric fashion, 
i.e., without having affinity to the [
35
S]TBPS binding site. Unlike niflumic acid that shows clear 
preference for inhibiting cerebellar granule cell layer GABAA receptors, the other fenamates 
showed little brain regional selectivity, indicating that their actions are not receptor-subtype 
selective. Of the non-fenamate NSAIDs studied at 100 µM concentration, diclofenac induced the 
greatest inhibition of the binding, which is not surprising as it has close structural similarity with 
the potent fenamate meclofenamic acid. Using two-electrode voltage-clamp assays on Xenopus 
oocytes, the effect of niflumic acid was found to be dependent on the β subunit variant and the 
presence of γ2 subunit in rat recombinant α1β and α1βγ2 GABAA receptors, with the β1 allowing 
the niflumic acid inhibition and β3 the stimulation of the receptor-mediated currents. In summary, 
the fenamate NSAIDs constitute an interesting class of compounds that could be used for 
development of potent GABAA receptor allosteric agonists with other targets to moderate 
inflammation, pain and associated anxiety/depression. 
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Painful conditions, such as arthritis and fibromyalgia, are comorbid with mental diseases, such as 
anxiety syndromes and depression (Grilli, 2017; Velly and Mohit, 2018). This interrelationship 
creates challenges to diagnosis and treatment options. Acute pain and inflammation are treated 
with nonsteroidal anti-inflammatory drugs (NSAIDs), but chronic neuropathic conditions might 
require drugs that have stronger actions in the central nervous system. However, some NSAIDs 
have been suggested to act directly e.g., on γ-aminobutyric acid type A receptors (GABAA), which 
constitute the main fast-acting inhibitory system in the brain. GABAA receptors are targeted by 
acutely efficacious anxiolytic and sedative drugs, such as benzodiazepines, hypnotics and various 
general anaesthetics (Korpi et al., 2002; Olsen and Sieghart, 2009). While activation of selected 
GABAA receptor subtypes have produced analgesia in some rodent models (Knabl et al., 2008; 
Munro et al., 2008; Ralvenius et al., 2015), especially in chronic pain the activation of the altered 
“excitatory” GABAA system might worsen the condition (Coull et al., 2005; Coull et al., 2003; Kahle 
et al., 2013). This makes the activation of this neurotransmitter system an unattractive option to 
treat pain conditions with anxiety. A further problem with GABAA receptor-activating drugs is 
caused by a rapid occurrence of tolerance and a risk of developing dependence and addiction 
(Korpi et al., 2015).  
 
It is well known that certain NSAIDs are unselective and not restricted to inhibition of 
cyclooxygenases (Cryer and Feldman, 1998; Vane and Botting, 2003; Vane, 2000). For instance, 
they also act on GABAA receptors. Especially the fenamates, mefenamic acid and niflumic acid 
have been reported to either stimulate or inhibit the functions of GABAA receptors in rodent 














antagonism by niflumic acid of selected GABAA receptor subtypes (Sinkkonen et al., 2003). 
Mefenamic acid, flufenamic acid and niflumic acid affect GABAA receptors expressed from poly(A)+ 
RNA isolated from rat cerebral cortex and expressed in Xenopus laevis oocytes (Woodward et al., 
1994), with low concentrations inducing potentiation and high concentrations inhibition. The 
potentiation was not blocked by flumazenil, indicating an effect not mediated by the high-affinity 
benzodiazepine sites. Niflumic acid had the lowest efficacy in potentiation, but the highest in 
inhibition, whereas mefenamic acid was strongly potentiating and weakly inhibiting. The effects of 
mefenamic acid on GABAA receptor function is dependent on the β subunits in a complex fashion 
(Halliwell et al., 1999). It facilitates the GABAA currents in recombinant α1β2 and α1β2γ3 
receptors, is inactive in α1β1γ2 and inhibitory in α1β1 receptors. The activation profile was traced 
to the well-known single amino acid residue “N290” in the β1 subunits. 
 
Here, we report for the first time on global effects of NSAIDs on mouse brain GABAA receptors, by 
studying brain regional effects of fenamates and other NSAIDs on the regulation of GABAA 





S]TBPS) with special emphasis on the GABA-insensitive 
atypical GABAA receptor populations as these are the only defined ones which can be easily 
visualized with [
35
S]TBPS binding (Halonen et al., 2009). Furthermore, we describe in more detail 
the subunit-dependencies of niflumic acid actions on a number of recombinant GABAA receptor 
subtypes heterologously expressed in Xenopus laevis oocytes. 
 
2. Materials and methods 
 















The autoradiographic data were collected using six male 2-month-old C57BL/6NHsd mice 
(Harlan Netherland, Horst, The Netherlands). The mice were briefly anesthetized using CO2 and 
decapitated, the brains dissected out and frozen on solid CO2 and stored at -80°C until sectioned. 
The electrophysiological data were from stage V-VI oocytes obtained from female Xenopus laevis 
frogs (Horst Kähler, Hamburg, Germany), anesthetized with 0.2% tricaine methanesulfonate 
(Sigma-Aldrich, St. Louis, MO, USA). Animal procedures were approved by the Southern Finland 




S]TBPS autoradiography  
 
We used 14-µm-thick horizontal cryostat sections thaw-mounted onto gelatin-coated 
object glasses from naive adult mice, cut with a Leica CM 3050S cryostat (Leica Microsystems, 
Benheim, Germany) (Korpi et al., 1992; Makela et al., 1997; Sinkkonen et al., 2001). The sections 
were preincubated in ice-cold buffer containing 50 mM Tris–HCl (pH 7.4) supplemented with 120 
mM NaCl for 15 min. We used two different assays. In the first one, we aimed at revealing 
allosteric drug sensitivities of the main GABA-sensitive GABAA receptor populations, with 
GABAergic agonists reducing the binding and antagonists increasing it (Korpi and Luddens, 1997). 
In the second one, we assessed the drug sensitivities of minor thalamus- and cerebellum-enriched 
atypical (GABA-insensitive, GIS) GABAA receptor populations (Halonen et al., 2009; Sinkkonen et 




S]TBPS) that we used is highly 
selective to GABAA receptors as compared to strychnine-sensitive glycine receptors (Rienitz et al., 
1987). The sections were incubated with 6 nM [
35
S]TBPS (Perkin-Elmer, Boston, MA, USA) in the 














either full or one sixth dilution radioactivity, for the GIS and main receptor populations, 
respectively. This was carried out in the presence and absence of GABA and drugs. Nonspecific 
binding was determined with 100 μM picrotoxinin (Sigma-Aldrich). For the study of the main 
receptor population, the sections were washed 3 x 15 s in ice-cold 10 mM Tris-HCl and quickly 
desalted in ice-cold distilled H2O. The GIS sections were washed 3 x 30 min in ice-cold 10 mM Tris-
HCl and quickly desalted in ice-cold distilled H2O. After the washing and air-drying, the sections 
were exposed to Biomax MR film (Eastman Kodak, Rochester, NY, USA) for 1-6 weeks with plastic 
14
C-radioactivity standards (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Binding densities 
in selected brain regions were quantitated with MCID IAS-imaging software (Imaging Research 
Inc., St. Catharine’s, Ontario, Canada) and standardized with radioactivity values on the basis of 
the simultaneously exposed standards. Nonspecific binding was subtracted from all values. 
 
2.3. Recombinant GABAA receptor subunits and preparation of cRNAs  
 
Capped cRNAs coding for rat GABAA receptor subunits α1, β1, β3, and γ2S (Luddens et al., 
1990; Shivers et al., 1989; Ymer et al., 1989) were transcribed in vitro from pRK5 plasmids with Sp6 
as promoter using mMessage mMachine kit (Ambion, Austin, TX, USA) according to 
manufacturer’s instructions. 
 
2.4. Oocyte electrophysiology of recombinant GABAA receptors 
 
Experiments using recombinant GABAA receptors were carried out as described in 
(Sinkkonen et al., 2003). In brief, isolated oocytes were stored in normal frog Ringer: 115 mM 














injected via a glass micropipette with 46 nl of a solution containing mixtures of subunit cRNAs 
(0.1–2.5 µg/µl) or pure H2O with Drummond Nanoject injector (Drummond Scientific Co., 
Broomall, PA, USA). The oocytes were incubated at 19°C in incubation solution [88 mM NaCl, 1 
mM KCl, 2.4 mM NaHCO3, 10 mM HEPES, 0.82 mM MgSO4, 0.33 mM Ca(NO3)2, 0.91 mM CaCl2, 0.5 
mM theophylline, 2 mM sodium pyruvate, 10 U/ml penicillin and 10 µg/ml streptomycin, pH 7.5]. 
After injection (2 h–1 day) oocytes were digested for 30 min in Ca
2+
-free medium (82.5 mM NaCl, 
2.5 mM KCl, 1 mM MgCl2, 1 mM Na2HPO4, and 5 mM HEPES, pH 7.5) containing 0.3 U/ml 
collagenase type IA (Sigma-Aldrich). Thereafter, the oocytes were incubated in incubation solution 
until recordings. For each experiment, oocytes from at least two different frogs were used. 
Electrophysiological recordings were made 1 to 3 days after cRNA injection. Oocytes were 
perfused with normal frog Ringer + drugs at a flow rate of 1 ml/min at room temperature (22°C) 
using an Ismatec pump (Ismatec, Glattbrugg-Zürich, Switzerland) and 17 channel perfusion system 
with pinch valves. 
Drug combinations were mixed before experiments. As negative control we employed 
furosemide which acts highly specifically on α6β2(γ2) and α6β3(γ2) receptors but not on α1 or β1 
subunit-containing receptors (Korpi et al., 1995; Korpi and Luddens, 1997). Niflumic acid at 1000 
µM concentration served as positive control. The GABA concentrations used in the experiments 
were chosen according to the expected EC75, GABA (except for α1β3γ2 receptors when EC25,GABA was 
used), which was in good agreement with the obtained GABA concentration-response curves for 
the four receptor subunit combinations (data not shown). We expected the largest effects of the 
analyzed compounds at this GABA concentration as the compounds were inhibitory in some 
receptor isoforms. 
As positive control oocytes were impaled with two microelectrodes (1.0–2.5 MΩ) filled 














voltage-clamp amplifier (NPI Electronic GmbH, Tamm, Germany). Experiments were controlled by 
Egg-Works experimental control and data acquisition software program version 3.0.2 (NPI 
Electronic GmbH). GABA was dissolved in NFR. Niflumic acid was dissolved in 0.1 M NaOH, stocks 
were diluted in NFR to a concentration of 10 mM, and pH was adjusted to 7.5. Drugs were applied 
for 10 s unless otherwise stated, and 180- to 600-s washout periods were used, depending on drug 
concentrations. In the GABA concentration-response experiments, any given GABA concentration 
was first applied alone and thereafter in the presence of niflumic acid.  
 
2.5. Drugs  
 
All fenamates and other NSAIDs were obtained from Sigma-Aldrich. They were dissolved at 
1 mM stock concentration into 0.1 M NaOH, and adjusted for pH 7.5 after final dilutions, if 
different from that.  
 
2.6. Data Analyses and Statistics  
 
Data analyses were performed using EggWorks Reader version 3.0.2 (NPI Electronic GmbH) 
and GraphPad Prism version 3.0 (GraphPad Software Inc., San Diego, CA) programs.  
For autoradiography, the specific [
35
S]TBPS binding values were determined by subtracting 
the nonspecific binding values from the corresponding total binding values under each incubation 
condition. To assess the statistical significance of the drug effects on [
35
S]TBPS binding, one-way or 
two-way analyses of variance (ANOVA) and Dunnett’s post hoc test were used. Student’s t test 














For electrophysiological recordings, the amplitudes of peak currents induced by GABA and 
drug applications were determined from recorded traces, normalized to the corresponding GABA-
induced peak currents estimated linearly between the GABA peak currents closest before and 
after the applications of GABA with the drugs, and presented as a percentage of the control GABA 
current. The peak currents induced by various GABA concentrations for each oocyte were 
normalized by setting the maximal GABA current without niflumic acid to 100%, and the GABA 
concentration-response curves were generated using nonlinear regression fit to a sigmoidal 
concentration-response curve. The statistical significance of the niflumic acid modulation of the 
GABA response was assessed with one-way ANOVA and Dunnett’s post hoc test. Furosemide and 




3.1. Effects of niflumic acid and other fenamates on GABAA receptor binding 
 
Previously, we have reported on a strong antagonism by niflumic acid of selected GABAA 
receptor subtypes (Sinkkonen et al., 2003). Now we wanted to determine whether the structurally 
close analogues flufenamic acid, meclofenamic acid, mefenamic acid and tolfenamic acid (Fig. 1) 
have similar effects. Concentration-response curves for these other fenamates clearly differed 
from those of niflumic acid in all brain regions. Niflumic acid had no effect on forebrain [
35
S]TBPS 
binding without added 3 µM GABA (Fig. 2), and only a minor inhibitory effect at the highest 
concentration in the presence of GABA. The other fenamates, except for flufenamic acid, robustly 
inhibited the binding at 10 µM concentration in both incubation conditions [one-way ANOVAs for 














the presence of GABA. The brain regional efficacy by the fenamates indicates a broad GABAA 
receptor subtype selectivity, unlike that detected previously for niflumic acid (Sinkkonen et al., 
2003) and confirmed here, as niflumic acid (10 µM) did not inhibit the [35S]TBPS binding without or 
with added 3 µM GABA, but rather increased it [F(6,35) = 67.5, P < 0.001; F(6,35) = 41.9, P < 0.001, 
respectively]. 
A high saturating GABA concentration (1 mM) abolished most of the picrotoxinin-sensitive 
[
35
S]TBPS binding in all brain regions, except for the thalamus and cerebellar granule cell layer, 
which retained 5-10% of the basal binding [Fig. 3, Table 1; (Sinkkonen et al., 2001)]. We also tested 
the effects of fenamates on this atypical GABA-insensitive binding component and found that the 
fenamates other than niflumic acid abolished this binding almost completely at micromolar 
concentrations [Fig. 3, Table 1; ANOVA F(8, 45) = 38,76, P < 0.0001 and F(9, 50) = 46,01, P < 0.0001 
for the thalamus and cerebellar granule cell layer, respectively], whereas niflumic acid at 100 µM 
failed to affect the thalamic binding and robustly enhanced the cerebellar granule cell layer 
binding, in agreement with (Sinkkonen et al., 2001).  The most potent fenamate appeared to be 
meclofenamic acid that reduced the binding to almost half in both brain regions at 1 µM 
concentration (Table 1). 
 
3.2. Effects of non-fenamate nonsteroidal anti-inflammatory drugs on GABAA receptor binding  
 
We then tested non-fenamate NSAIDs (Fig. 1) for their effects on [
35
S]TBPS binding with or 
without added 3 µM GABA in various brain regions. All brain regions showed sensitivity to some of 
the NSAIDs [Fig. 4; 2-way ANOVAs for brain region F(6,231) = 684.7, P < 0.0001, drug F(10,231) = 
18.54, P < 0.0001, and brain region x drug interaction F(60, 231) = 1.3, P > 0.05, and for brain 














interaction F(60, 231) = 10.7, P < 0.0001, for the total binding and for the binding in the presence 
of 3 µM GABA, respectively]. Most drugs at 100 µM concentration failed to affect basal and GABA-
inhibited binding (Fig. 4), but diclofenac and MF-tricyclic clearly inhibited the binding in the 
presence of GABA, but had hardly any effects without it. Also rofecoxib had some inhibitory 
effects on the binding, but less consistently than diclofenac and MF-tricyclic. 
 
3.3. Molecular determinants of niflumic acid action on recombinant GABAA receptors 
 
Since niflumic acid effects are markedly different from those of other fenamates, we 
wanted to gain insight on which features of the GABAA receptor subunits its actions depend. To 
that aim we investigated niflumic acid’s action on four defined GABAA receptor subtypes by 
measuring its effect on GABA-induced Cl
-
-influx into Xenopus laevis oocytes injected with rat α1 
subunit RNA together with either the rat β1 or rat β3 subunit RNA. Additionally, we looked at the 
action of this fenamate on GABA-induced currents of rat α1β1γ2 and α1β3γ2 receptors. 
For both receptors lacking the γ2 subunit niflumic acid dose-dependently decreased the 
GABA-induced current [Fig. 5A; niflumic acid effect F(4,50) = 73.2, P < 0.0001; receptor effect 
F(1,50) = 87.0, P < 0.0001], though niflumic acid was more potent on β1- than on β3-containing 
receptors by a factor >10 (Fig. 5B). When α1/β1 and α1/β3 RNA was co-injected with γ2 RNA, 
α1β1γ2 receptor responses to GABA were still inhibited by increasing concentrations of niflumic 
acid [Fig. 6 A, B; niflumic acid effect F(4,50) = 751.2, P < 0.0001; receptor effect F(1,50) = 6.9, P < 


















Global, strong effects of the fenamates and some other NSAIDs on brain GABAA receptors 
indicate either effects on the main receptor subtypes (e.g., α1β2γ2 receptors) or very strong 
effects on minor subtypes, such as α1β3γ2 receptors. In the absence of saturating 1-mM GABA 
concentration, the active fenamate drugs behaved like agonists (Korpi et al., 1996; Makela et al., 
1997), reducing the binding of the channel ligand [
35
S]TBPS practically in all brain regions, except 
for niflumic acid in the cerebellar cortex. We have reported on the antagonist-like action of 
niflumic acid on GABAA receptors in the cerebellar granule cell layer (see also Figs 2-3, Table 1), 
which effect is dependent on α6 subunit-containing GABAA receptors (Sinkkonen et al., 2003). 
Here, we found that the other studied fenamates did not recapitulate this effect, but had agonist-
like effect also in the cerebellum. Furthermore, the fenamates reduced the GABA-insensitive 
[
35
S]TBPS binding component, which is dependent on α1 subunit-containing receptors in the 
forebrain and on α6 containing receptors in the cerebellum (Halonen et al., 2009). Thus, our 
results suggest that the fenamates have the potential to enhance the function of a wide range of 
GABAA receptor subtypes in the brain. However, we could not establish any clear structure-activity 
relationship for their activity. 
Of the non-fenamate NSAIDs that had agonist-like activity, the clinically widely used 
diclofenac was the most interesting (Fig. 4). Its structure resembles those of the fenamates (Fig. 1) 
and it did cause a significant reduction in the binding of [
35
S]TBPS in most brain regions (Fig. 4B). 
Also the experimental MF-tricyclic and the newer cyclooxygenase-2-selective rofecoxib had some 
agonist-like effect, but the other drugs tested were rather inactive in this assay. Some NSAIDs have 
been shown to potentiate the antagonistic effects of quinoline-antibiotics on GABAA receptors. 
Thus, the antagonism by enoxacin, a guinolone antibiotic, on GABAA responses in frog dorsal root 














piroxicam and paracetamol (Yakushiji et al., 1992). It should be kept in mind that fenamates 
[flufenamic acid as an example (Guinamard et al., 2013)] and diclofenac have multiple ion channel 
targets other than GABAA receptors that can contribute to clinical efficacy and adverse effects, 
albeit often at higher concentrations than needed to inhibit cyclooxygenases (Gwanyanya et al., 
2012). 
The effects of niflumic acid on recombinant GABAA receptor function was dependent on 
the β and γ subunits in a complex fashion. Niflumic acid had inhibitory effects on GABA-induced 
currents in α1β1, α1β3 and α1β1γ2 recombinant receptors, whereas the effect was positive in 
α1β3γ2 receptors (Fig. 5 and 6). This is partially in line with the finding that mefenamic acid 
facilitates the GABAA currents at recombinant α1β2 and α1β2γ3 receptors, is inactive at α1β1γ2 
and inhibitory at α1β1 receptors (Halliwell et al., 1999). The activation profile was traced to a 
single amino acid residue “N290” in the β2/3 subunits, which appears to mediate the effects of a 
number of drugs on GABAA ion channels [for pharmacological listing of these compounds, see 
(Sieghart and Savic, 2018)]. Other fenamates have a similar profile as mefenamic acid (Smith et al., 
2004). Since the β1 subunit-containing receptors have been suggested to mediate sedative drug 
actions more readily than β3 containing receptors, the fenamates should not be very sedative. 
However, the latter receptors are thought to be more involved in anaesthesia than β1 receptors 
(Jurd et al., 2003; Yanovsky et al., 2012). 
Fenamates are also functionally active on native GABAA receptors, e.g. in cultured primary 
hippocampal neurons from rats (Coyne et al., 2007). Oral administration of mefenamic acid to 
mice results in such high brain concentrations that should be relevant for potentiating GABAA 
receptors (Gee et al., 2010). Indeed, mefenamic acid has been shown to be neuroprotective in 
adult male Wistar rats in a transient ischemic stroke model (Khansari and Halliwell, 2009). As well, 














ibuprofen and indomethacin not (Ikonomidou-Turski et al., 1988). In that study, high doses (30-40 
mg/kg) of mefenamic acid induced sedation and reduced muscle tone. Mefenamic acid ip 5 mg/kg 
daily for 3 weeks reduced learning deficits in a rat model of Alzheimer’s disease (Joo et al., 2006). 
Tolfenamic acid has been reported to have therapeutic effect on alcohol hangover and migraine 
attacks (Hakkarainen et al., 1979; Parantainen, 1983). All these results suggest that fenamates are 
taken up into the CNS at efficient concentrations. Though the carboxy groups provide some 
polarity to all fenamates studied, the calculated partition coeffcients (logP values ranged from 4.3 
to 5.1) between water and oil [(Tetko et al., 2005) http://vcclab.org] do not contradict their 
passage of the blood brain barrier (Pajouhesh and Lenz, 2005). We are not aware of any studies on 
possible GABAA receptor-mediated anxiolytic effects of NSAIDs and especially those of fenamates. 
On the contrary, intracerebroventricular infusion in rats of niflumic acid and flufenamic acid 
reduced high-dose ethanol-induced loss of righting reflex as a measure of alcohol intoxication, but 
not low dose-induced sedation (Carter et al., 2016), which was correlated with their antagonism of 
calcium-activated anion channels. Thus, any agonistic effect on GABAA receptors should have 
potentiated the alcohol sedation.  
Very recently there have been efforts to develop positron emission tomography ligands for 
cyclooxygenase 1 and 2. The first reports with monkeys have suggested that both COX-1 (Kim et 
al., 2018) and COX-2 (Kumar et al., 2018) ligands pass through the blood-brain barrier producing 
partially pharmacologically specific accumulation in selected brain structures.  
 
5. Conclusions 
Our results indicate robust agonist-like effect of fenamates and some other NSAIDs on the 
main fast-acting inhibitory neurotransmitter system, GABAA receptor, in the brain. It remains to be 














neuropsychiatric symptoms, and whether these drugs could be used to develop even more potent 
allosteric agonists without losing the anti-inflammatory efficacy. 
The fenamates and diclofenac were the compounds with the highest efficacy in most brain 
regions studied under basal conditions as well as in the presence of 3 µM GABA, whereas e.g. the 
structurally unrelated sulindac was effective only in the latter condition for GABAA receptor 
subpopulation in the inferior colliculus and the thalamus. Furthermore, whereas the fenamates 
and diclofenac further inhibited [
35
S]TBPS binding, sulindac potentiated it, suggesting that 
different NSAIDs might have different effects on co-morbid symptoms in pain conditions. 
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Table 1. The differential effects of niflumic acid vs. other fenamates on GABA-insensitive [
35
S]TBPS 
binding to GABAA receptors in the mouse thalamus and cerebellar granule cell layer.  






Flufenamic acid Meclofenamic 
acid 
Mefenamic acid Tolfenamic acid 
 nCi/g  100 µM 3 µM 30 µM 1 µM 10 µM 1 µM 10 µM 1 µM 10 µM 
Thalamus 38 ± 4 5 ± 1 97 ± 4 76 ± 11 11 ± 6
 a




 114 ± 6 5.1 ± 3.2
 a
 115 ± 13 0
 a
 
CbGCL 35 ± 2 11 ± 1 343 ± 33
a
 81 ± 18 23 ± 11
 a
  65 ± 8
 a
 3 ± 2
 a
 93 ± 5 20 ± 8
 a




Values for the fenamates are mean percentages ± S.E.M. of the corresponding values in the 
presence of a saturating concentration of GABA alone (n = 6 mice). CbGCL, cerebellar granule cell 
layer. See Figure 3 for representative images. 
a
 P < 0.001 for the significance of the difference from the 1-mM GABA-inhibited binding (ANOVA, 
















Legends to figures 
 
Fig. 1.  Structures of the anti-inflammatory compounds and paracetamol studied for their effects 
on GABAA receptors with the 2-(phenylamino)benzoic acid moiety being the IUPAC name of 
fenamic acid in the first five compounds and diclofenac being a closely related structure. 
 
Fig. 2. Effects of fenamates on basal and GABA-inhibited [
35
S]TBPS binding to GABAA receptors in 
various mouse brain regions. (A) Representative images, demonstrating clear enhancement of the 
GABA effect on binding in all brain regions by 10 µM concentrations of the fenamates other than 
niflumic acid and in some areas flufenamic acid. Ctx, cerebral cortex; CbGCL, cerebellar granule 
cell layer; Hi, hippocampus; IC, inferior colliculus; Str, striatum; Th, thalamus. (B) Concentration-
response curves for the effects of fenamates on basal binding. (C) Concentration-response curves 
for the effects of fenamates on 3-µM GABA-inhibited binding. The data points are means ± S.E.M. 
of the corresponding GABA values (n = 4-6).  
 
Fig. 3. The effects of fenamates on atypical GABA-insensitive binding of [
35
S]TBPS to GABAA 
receptors in mouse brain sections. Picrotoxinin (Ptx) was used to define the nonspecific (NS) 
binding in the presence of saturating high concentration of GABA (1 mM). Nifl, niflumic acid; Mecl, 
meclofenamic acid; Mefe, mefenamic acid; Tolf, tofenamic acid. Flufenamic acid produced visually 
similar images as the fenamates other than niflumic acid, but were accidentally smeared on 
sections, allowing quantification of the thalamic and cerebellar granule cell layer (CbGCL) bindings 
(Table 1) but not imaging. The number indicate micromolar concentrations. Note that niflumic 
acid antagonized the effect of GABA in the CbGCL, while the other fenamates almost fully 














Fig. 4. The effects of nonsteroidal anti-inflammatory drugs on the basal and GABA-inhibited 
[
35
S]TBPS binding to GABAA receptors in various mouse brain regions. (A) Representative images, 
demonstrating enhancement of the 3-µM GABA effect on binding by the positive control, 
fenamate meclofenamic acid (Mecl, at 1 µM, see Fig. 2BC), and by 100 µM concentrations of 
diclofenac (Dicl), rofecoxib (Rof) and MF-tricyclic (MF), but not by paracetamol (Par, 
acetaminophen), which slightly increased the binding in some brain regions in the presence of 
GABA. Ctx, cerebral cortex; (Cb)GCL, cerebellar granule cell layer; Hi, hippocampus; IC, inferior 
colliculus; (Cb)ML, cerebellar molecular layer; Str, striatum; Th, thalamus. (B) Regional effects of 
the studied NSAIDs on [
35
S]TBPS binding in selected brain regions. Bars are means + S.E.M. (n=4).  
* P < 0.05, 
& 
P < 0.01, 
#
 P < 0.001 for the significance of the difference from the basal or GABA-
inhibited binding in the absence of drugs within the brain region (ANOVA, followed by Dunnett’s 
test). 
 
Fig. 5. (A) Representative current traces of niflumic acid and furosemide modulation on 10 µM and 
20 µM GABA-induced currents in recombinant α1β1 and α1β3 GABAA receptors expressed in 
Xenopus laevis oocytes. n = 7 and 5 for α1β1 and α1β3 combinations, respectively. F100, 
furosemide 100 µM. (B) Niflumic acid effects represented as mean percentage ± S.E.M., the GABA 
30 µM and GABA 20 µM control responses being set to 100 %. F, furosemide 100 µM + GABA  30 
µM or GABA 20 µM; N, 1000 µM niflumic acid alone. *** P < 0.001 for the significance of the 
difference from the corresponding control value (one-way ANOVA, followed by Dunnett’s test for 
niflumic acid in the presence of GABA, Student’s t-test for furosemide or niflumic acid alone). The 
dashed line represents the GABA control value. The EC50 values were 6.1 ± 1.3 µM and 10.6 ± 1.1 














Fig. 6. (A) Representative current traces of niflumic acid and furosemide modulation on 30 µM and 
20 µM GABA-induced currents in recombinant α1β1γ2 and α1β3γ2 GABAA receptors, respectively, 
expressed in Xenopus laevis oocytes. n = 7 and 5 for α1β1γ2 and α1β3γ2 combinations, 
respectively. F, furosemide 100 µM. (B) Niflumic acid effects represented as mean percentage ± 
S.E.M., the GABA  30 µM and GABA 20 µM control response being set to 100 %. F, furosemide 100 
µM + GABA 30 µM or GABA 20 µM; N, 1000 µM niflumic acid alone. * P < 0.05, *** P < 0.001 for 
the significance of the difference from the corresponding control value (one-way ANOVA, followed 
by Dunnett’s test for niflumic acid in the presence of GABA, Student’s t-test for furosemide or 
niflumic acid alone). The dashed line represents the GABA control value. The EC50 values were 14.3 
± 3.8 µM and 33.0 ± 7.6 µM for α1β1γ2 and α1β3γ2, respectively. 
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